Explore ›
Finding
Finding
adverse
In the sacral neuromodulation group, 3% of women (6 of 189) had their device revised or removed during the 6-month period.
| Effect size | 3% (6 of 189 women) |
| Follow-up | 6 months |
| Comparator | OnabotulinumtoxinA (no device) |
| Effect summary | adverse; 3% (6 of 189 women) |
| Adverse events | device revision or removal 3% |
Connected entities
Interventions
Conditions
Outcomes
Populations
Source
PMC5399419
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial